Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[To compare the performance characteristics of prostate cancer risk factors such as total prostate-specific antigen (tPSA), percentage free PSA (%fPSA), PSA velocity (PSAV) and urinary prostate cancer gene 3 (PCA3) at first, second and ? third repeat biopsy session.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP182456.RAfs6koHvhGtrncTYMhrPQKlzNZHwnLxzGcumpcAp2KK8130_assertion description "[To compare the performance characteristics of prostate cancer risk factors such as total prostate-specific antigen (tPSA), percentage free PSA (%fPSA), PSA velocity (PSAV) and urinary prostate cancer gene 3 (PCA3) at first, second and ? third repeat biopsy session.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP182456.RAfs6koHvhGtrncTYMhrPQKlzNZHwnLxzGcumpcAp2KK8130_provenance.
• NP213058.RAtuRwphFdQ44PpgWnY1zd6MSak4CSCDZaE1ifkWSRpJk130_assertion description "[To compare the performance characteristics of prostate cancer risk factors such as total prostate-specific antigen (tPSA), percentage free PSA (%fPSA), PSA velocity (PSAV) and urinary prostate cancer gene 3 (PCA3) at first, second and ? third repeat biopsy session.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP213058.RAtuRwphFdQ44PpgWnY1zd6MSak4CSCDZaE1ifkWSRpJk130_provenance.
• assertion description "[To compare the performance characteristics of prostate cancer risk factors such as total prostate-specific antigen (tPSA), percentage free PSA (%fPSA), PSA velocity (PSAV) and urinary prostate cancer gene 3 (PCA3) at first, second and ? third repeat biopsy session.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[To compare the performance characteristics of prostate cancer risk factors such as total prostate-specific antigen (tPSA), percentage free PSA (%fPSA), PSA velocity (PSAV) and urinary prostate cancer gene 3 (PCA3) at first, second and ? third repeat biopsy session.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[To compare the performance characteristics of prostate cancer risk factors such as total prostate-specific antigen (tPSA), percentage free PSA (%fPSA), PSA velocity (PSAV) and urinary prostate cancer gene 3 (PCA3) at first, second and ? third repeat biopsy session.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[To compare the performance characteristics of prostate cancer risk factors such as total prostate-specific antigen (tPSA), percentage free PSA (%fPSA), PSA velocity (PSAV) and urinary prostate cancer gene 3 (PCA3) at first, second and ? third repeat biopsy session.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[To compare the performance characteristics of prostate cancer risk factors such as total prostate-specific antigen (tPSA), percentage free PSA (%fPSA), PSA velocity (PSAV) and urinary prostate cancer gene 3 (PCA3) at first, second and ? third repeat biopsy session.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[To compare the performance characteristics of prostate cancer risk factors such as total prostate-specific antigen (tPSA), percentage free PSA (%fPSA), PSA velocity (PSAV) and urinary prostate cancer gene 3 (PCA3) at first, second and ? third repeat biopsy session.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[To compare the performance characteristics of prostate cancer risk factors such as total prostate-specific antigen (tPSA), percentage free PSA (%fPSA), PSA velocity (PSAV) and urinary prostate cancer gene 3 (PCA3) at first, second and ? third repeat biopsy session.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[To compare the performance characteristics of prostate cancer risk factors such as total prostate-specific antigen (tPSA), percentage free PSA (%fPSA), PSA velocity (PSAV) and urinary prostate cancer gene 3 (PCA3) at first, second and ? third repeat biopsy session.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP925651.RAb1Z2-DslXlhVuoaQha377o0RYm5k2wDzNlH_wQqye0o130_assertion description "[To compare the performance characteristics of prostate cancer risk factors such as total prostate-specific antigen (tPSA), percentage free PSA (%fPSA), PSA velocity (PSAV) and urinary prostate cancer gene 3 (PCA3) at first, second and ? third repeat biopsy session.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP925651.RAb1Z2-DslXlhVuoaQha377o0RYm5k2wDzNlH_wQqye0o130_provenance.
• NP925658.RAWYLvd2W58pVjYmL3HUkjLHaP2iLFoMa3G4KZIwZFP20130_assertion description "[To compare the performance characteristics of prostate cancer risk factors such as total prostate-specific antigen (tPSA), percentage free PSA (%fPSA), PSA velocity (PSAV) and urinary prostate cancer gene 3 (PCA3) at first, second and ? third repeat biopsy session.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP925658.RAWYLvd2W58pVjYmL3HUkjLHaP2iLFoMa3G4KZIwZFP20130_provenance.
• NP925657.RADoLpcfFwJrH-8nthYI4hO0_BWjsg08IL0MC2w8joodA130_assertion description "[To compare the performance characteristics of prostate cancer risk factors such as total prostate-specific antigen (tPSA), percentage free PSA (%fPSA), PSA velocity (PSAV) and urinary prostate cancer gene 3 (PCA3) at first, second and ? third repeat biopsy session.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP925657.RADoLpcfFwJrH-8nthYI4hO0_BWjsg08IL0MC2w8joodA130_provenance.
• NP925652.RAqjiQNmqybTx1ePAYHKaX3aLCY-YHKd43rojmbFUjSyU130_assertion description "[To compare the performance characteristics of prostate cancer risk factors such as total prostate-specific antigen (tPSA), percentage free PSA (%fPSA), PSA velocity (PSAV) and urinary prostate cancer gene 3 (PCA3) at first, second and ? third repeat biopsy session.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP925652.RAqjiQNmqybTx1ePAYHKaX3aLCY-YHKd43rojmbFUjSyU130_provenance.
• NP925659.RAv0bFteYyqpSWB6rpWU0wituIlPLbNc6BaktWcAR3nrU130_assertion description "[To compare the performance characteristics of prostate cancer risk factors such as total prostate-specific antigen (tPSA), percentage free PSA (%fPSA), PSA velocity (PSAV) and urinary prostate cancer gene 3 (PCA3) at first, second and ? third repeat biopsy session.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP925659.RAv0bFteYyqpSWB6rpWU0wituIlPLbNc6BaktWcAR3nrU130_provenance.
• NP925660.RAvwst64mdiK0V43AVlBP_SzygRrW7QxDzBXI658DMllg130_assertion description "[To compare the performance characteristics of prostate cancer risk factors such as total prostate-specific antigen (tPSA), percentage free PSA (%fPSA), PSA velocity (PSAV) and urinary prostate cancer gene 3 (PCA3) at first, second and ? third repeat biopsy session.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP925660.RAvwst64mdiK0V43AVlBP_SzygRrW7QxDzBXI658DMllg130_provenance.
• NP925662.RAPQytVgaFUUKkglfO2EVyMaL7FHXq9-Xv-ug3XtmOtTQ130_assertion description "[To compare the performance characteristics of prostate cancer risk factors such as total prostate-specific antigen (tPSA), percentage free PSA (%fPSA), PSA velocity (PSAV) and urinary prostate cancer gene 3 (PCA3) at first, second and ? third repeat biopsy session.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP925662.RAPQytVgaFUUKkglfO2EVyMaL7FHXq9-Xv-ug3XtmOtTQ130_provenance.
• NP925653.RA-9BoUBKE83MM5LTweMN_G18BD6ryAleR-ZmhJ3eJQgA130_assertion description "[To compare the performance characteristics of prostate cancer risk factors such as total prostate-specific antigen (tPSA), percentage free PSA (%fPSA), PSA velocity (PSAV) and urinary prostate cancer gene 3 (PCA3) at first, second and ? third repeat biopsy session.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP925653.RA-9BoUBKE83MM5LTweMN_G18BD6ryAleR-ZmhJ3eJQgA130_provenance.
• NP925654.RA4jzXEHD_ph_HYJg6PzzFmhfglwVjghFidNkioIqM5L0130_assertion description "[To compare the performance characteristics of prostate cancer risk factors such as total prostate-specific antigen (tPSA), percentage free PSA (%fPSA), PSA velocity (PSAV) and urinary prostate cancer gene 3 (PCA3) at first, second and ? third repeat biopsy session.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP925654.RA4jzXEHD_ph_HYJg6PzzFmhfglwVjghFidNkioIqM5L0130_provenance.
• NP925655.RAyEW0DSyB0HKvFQOwbWeKRl-owKNpxBwaRUCHWzGDdls130_assertion description "[To compare the performance characteristics of prostate cancer risk factors such as total prostate-specific antigen (tPSA), percentage free PSA (%fPSA), PSA velocity (PSAV) and urinary prostate cancer gene 3 (PCA3) at first, second and ? third repeat biopsy session.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP925655.RAyEW0DSyB0HKvFQOwbWeKRl-owKNpxBwaRUCHWzGDdls130_provenance.